Is Ionis Pharmaceuticals (IONS) Undervalued After TRYNGOLZA EU Approval And Diranersen Data?
Ionis Pharmaceuticals (IONS) is under scrutiny after receiving European approval for TRYNGOLZA and presenting Phase 2 data for diranersen, yet its share price has fallen significantly. Analysts view the company as 61% undervalued, with a fair value of $69.30, based on the potential of its APOC3 and neurology franchises. However, a sales-based valuation suggests a mixed picture with the stock trading at a premium to its fair P/S ratio, indicating both opportunity and risk for investors.
Guggenheim cuts Ionis stock price target to $65 on revenue miss
Guggenheim has reduced its price target for Ionis Pharmaceuticals (NASDAQ:IONS) from $80 to $65, while maintaining a Buy rating, following a third-quarter revenue miss for its drug TRYNGOLZA. The stock is currently trading near its 52-week low and is down 66% year-to-date. The revenue shortfall is attributed to slow prescriber adoption and payer policies, prompting other firms like TD Cowen, RBC Capital, Wells Fargo, BofA Securities, and Raymond James to also lower their price targets for Ionis.
Ionis, Sobi granted EU label expansion for Tryngolza
Ionis Pharmaceuticals announced that the European Commission has approved a label expansion for its lipid-lowering agent, Tryngolza, which is marketed with Swedish firm Sobi. This approval allows the RNA-targeting therapy to be used for an expanded indication, in addition to its existing use for familial chylomicronemia syndrome.
What Investors Got Wrong About Ionis Pharmaceuticals Before A 65% Slide
Ionis Pharmaceuticals experienced a 65% stock slide despite positive headlines like FDA approvals and revenue growth. Investors underestimated the path to profitability, focusing too much on growth rather than how quickly rising sales would narrow losses. The current share price of US$28.01 is significantly below its starting point, with a bullish analyst narrative still placing its Fair Value higher based on the potential of recent approvals to drive sustained adoption and profitability.
H.C. Wainwright Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $70
H.C. Wainwright has reiterated its Buy rating for Ionis Pharmaceuticals (IONS.US) and maintained its target price of $70. This indicates the firm's continued confidence in the company's financial prospects and stock performance.
Ionis Stock Is Up 6.4% What's Changed After Two Year HAE Data
Ionis Pharmaceuticals' stock rose 6.4% after reporting Q3 2026 revenue of US$242.72 million and a net loss of US$109.97 million, while reaffirming full-year revenue guidance. The increase is primarily driven by new two-year data for DAWNZERA, which demonstrated significant reductions in hereditary angioedema attack rates and a consistent safety profile. This data strengthens the company's rare disease portfolio, though commercial uptake of other launched drugs remains a key near-term catalyst.
Earnings Update: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Just Reported And Analysts Are Trimming Their Forecasts
Ionis Pharmaceuticals recently released its quarterly earnings report, which led analysts to revise their financial forecasts downwards for the coming year. This adjustment reflects a more conservative outlook on the company's future performance following the latest results. Investors will be closely watching how the company navigates these revised expectations.
Blueprint's Kate Haviland: Why Drug Launches Miss — Ionis's $9 Million Quarter Is the Latest Warning
Kate Haviland, former CEO of Blueprint Medicines, argues that drug launches frequently fail due to companies and analysts underestimating "the last mile," which includes diagnostic delays, physician habits, and payer friction, rather than misjudging market size. She highlights Ionis's recent $9 million launch quarter against a $20 million consensus as a prime example. Haviland suggests that effective launch forecasting requires triangulating field visits with non-KOL physicians, large tracking surveys, and machine-learning claims data, rather than relying on expert network calls.
The Strategy Exited Ionis Pharmaceuticals (IONS) Following Sequential Phase 3 Clinical Setbacks
Artisan Partners' "Artisan U.S. Small-Cap Growth Strategy" exited its investment in Ionis Pharmaceuticals (NASDAQ:IONS) after the company experienced two sequential Phase 3 clinical trial setbacks. These disappointments, involving eplontersen for cardiomyopathy and pelacarsen for Lp(a), reduced the firm's confidence in Ionis's profit cycle. Despite a challenging quarter for small-cap growth stocks overall, the strategy's healthcare sector showed positive performance.
US$76.30: That's What Analysts Think Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Is Worth After Its Latest Results
Ionis Pharmaceuticals, Inc. reported strong quarterly results with revenues exceeding analyst forecasts, but analysts subsequently lowered their 2027 revenue estimates and significantly increased loss per share expectations. This shift led to a 9.3% reduction in the consensus price target to US$76.30, indicating a mixed view on the company's future despite an anticipated acceleration in revenue growth faster than the industry average.
Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors
Wolf Popper LLP is investigating potential claims on behalf of purchasers of Ionis Pharmaceuticals, Inc. common stock. This investigation follows a significant drop in Ionis's stock price after the company announced lower-than-anticipated sales for its drug TRYNGOLZA and subsequently lowered its full-year sales guidance for the drug. The firm is inviting investors who suffered losses to contact them to discuss the investigation.
Ionis Pharmaceuticals stock hits 52-week low at $27.71 By Investing.com
Ionis Pharmaceuticals Inc. stock recently hit a 52-week low of $27.71, marking a significant 59.84% decline over the past year. This drop follows a revenue miss for its drug Tryngolza, prompting several analysts to lower price targets while maintaining generally positive ratings. The company, with a market cap of $4.66 billion, is considered undervalued by InvestingPro, and its RSI suggests the stock is in oversold territory.
Here's Why Ionis Pharmaceuticals' Stock is Down 28.5% Post Q3 Earnings
Ionis Pharmaceuticals' stock dropped 28.5% despite better-than-expected Q3 2026 earnings, primarily due to the slower-than-anticipated launch of Tryngolza and a significant reduction in its full-year sales guidance. Additionally, Wainua royalties disappointed investors, and competitive pressures, particularly from Arrowhead Pharmaceuticals, add to the company's concerns. The company also pushed back its target for sustained positive cash flow by one year to 2029.
Ionis Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ionis Pharmaceuticals (IONS)
Levi & Korsinsky is investigating Ionis Pharmaceuticals (NASDAQ: IONS) following a significant cut in its full-year 2026 TRYNGOLZA product sales guidance. The company initially projected $100 million to $110 million in sales, but on November 9, 2026, lowered this target to approximately $50 million, causing a sharp decline in share price. The investigation focuses on whether Ionis made misleading statements regarding its sales guidance prior to this disclosure.
IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals
SueWallSt is investigating Ionis Pharmaceuticals (NASDAQ: IONS) on behalf of investors who suffered losses after the company cut its full-year TRYNGOLZA product sales guidance by more than 50% on November 9, 2026, despite beating third-quarter revenue estimates. This significant guidance reduction led to a sharp decline in IONS shares, prompting concerns about potentially misleading statements made prior to the disclosure. Investors who purchased shares before the announcement and incurred losses are encouraged to review their legal rights.
Wells Fargo cuts Ionis Pharmaceuticals price target on slower launch
Wells Fargo has lowered its price target for Ionis Pharmaceuticals (NASDAQ:IONS) from $95 to $80, while maintaining an Overweight rating, due to a slower-than-expected launch of the drug Tryngolza and reduced expectations for sHTG. Despite the price target cut, Ionis reported stronger-than-expected Q3 2026 non-GAAP EPS and revenue, though it revised down its fiscal year 2026 Tryngolza sales guidance and pushed back its cash flow breakeven target to 2029. Other firms, BofA Securities and Raymond James, also reduced their price targets for Ionis, citing similar concerns about Tryngolza's launch.
Ionis Pharmaceuticals shares plummet after slow rollout of biotech’s triglyceride-lowering drug
Ionis Pharmaceuticals' shares dropped significantly after the company reduced its sales projections for its triglyceride-lowering drug, Tryngolza. The biotech firm now expects $50 million in sales by year-end, a substantial decrease from its initial forecast of $100 to $110 million, with third-quarter sales falling well below Wall Street expectations. Analysts suggest that doctors have been slow to prescribe the drug, leading to a 25% drop in stock value.
Ionis Pharmaceuticals Delivers 55% Revenue Growth in Q3 2026
Ionis Pharmaceuticals (NASDAQ:IONS) reported a strong third-quarter beat in 2026, with revenue growing 55% year-over-year to $243.0M, significantly exceeding Wall Street's forecast. The company's loss per share narrowed to $0.66, and its flagship product, SPINRAZA, continued its impressive growth. Management also raised its full-year revenue guidance, leading to a positive market reaction.
Why Is Ionis Pharmaceuticals Stock at a 52-Week Low on Monday?
Ionis Pharmaceuticals (NASDAQ: IONS) stock hit a 52-week low on Monday after the company reduced its 2026 product sales guidance for Tryngolza, a cholesterol-lowering drug, from an expected $100-$110 million down to $50 million. Despite beating Wall Street expectations for Q3 financial results and affirming its overall 2026 sales guidance, the slower-than-anticipated launch of Tryngolza for severe hypertriglyceridemia (sHTG) is impacting investor confidence. The company's leadership remains confident in Tryngolza's long-term multibillion-dollar peak sales potential, emphasizing strategic initiatives to expand its prescriber base and improve payer access.
Ionis reports third quarter 2026 financial results and highlights progress on key programs
Ionis Pharmaceuticals reported its third-quarter 2026 financial results, highlighting three new medicine approvals, including ZANVASTRO for Alexander disease and HIBSAGO for chronic hepatitis B. While TRYNGOLZA's product sales guidance was lowered due to a more gradual launch, the company reaffirmed its overall 2026 total revenue, operating loss, and cash guidance, expressing confidence in the long-term potential of its commercial and pipeline programs. The report also detailed ongoing launches and clinical advancements for other key medicines like DAWNZERA, SPINRAZA, and WAINUA.
IONS: SEC Form 10-Q filed by Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc. filed its Q3 2026 10-Q report, indicating a net loss for the three and nine months ended September 30, 2026, and an accumulated deficit of approximately $2.9 billion. The company reported $9.6 billion in revenue since inception and began commercial sales of ZANVASTRO in September 2026. Future revenue is expected to primarily come from commercial sales, requiring continued significant investment.
Ionis Pharmaceuticals Q3 Results: Sales up 54.78% to $243 million
Ionis Pharmaceuticals reported a significant 54.78% year-over-year increase in Q3 sales, reaching $243 million and surpassing analyst estimates by 33.43%. The company also narrowed its adjusted loss per share to $(0.40), beating the consensus estimate by nearly 67%. Despite strong revenue growth, the slower reduction in net loss suggests that cost structures or non-operating expenses did not scale down at the same rate.
Ionis Pharmaceuticals | 8-K: Ionis reports third quarter 2026 financial results and highlights progress on key programs
Ionis Pharmaceuticals has released its third quarter 2026 financial results, which are detailed in an 8-K filing. The report also highlights the company's significant progress on its key development programs, indicating advancements in its therapeutic pipeline.
Ionis Pharmaceuticals Reports 55% Rise in Q3 Revenue to $243 Million, Cuts TRYNGOLZA Sales Guidance
Ionis Pharmaceuticals reported a 55% increase in third-quarter 2026 revenue to $243 million, driven by commercial product sales and research partnerships. Despite this growth, the company lowered its full-year sales guidance for TRYNGOLZA to $50 million due to a slower-than-anticipated launch. Ionis maintained its overall 2026 financial guidance for total revenue and non-GAAP operating loss.
Ionis Pharmaceuticals (IONS) Stock Price, Chart & Analysis
This article provides a detailed analysis of Ionis Pharmaceuticals (IONS) stock, covering its current price, market capitalization, and key financial figures. It assesses the company's quality, growth, and valuation using various metrics and offers different scenarios for future price performance based on analyst forecasts, though it explicitly states this is not investment advice.
Pelacarsen Trial Failure Might Change The Case For Investing In Ionis Pharmaceuticals Stock (IONS)
Ionis Pharmaceuticals' stock (IONS) faces a significant setback after its pelacarsen trial failed to reduce major cardiovascular events, eliminating a key anticipated royalty source. This trial failure adds pressure on the company, which is already grappling with shrinking revenue and net losses, making its APOC3, neurology, and rare disease franchises critical for future success. The news prompts a reassessment of Ionis's investment narrative, shifting focus to other pipeline drugs and partnered programs to drive profitability amidst diminished cardiovascular upside.
Novartis is said to be abandoning Ionis heart drug after late-stage trial setback
Novartis is reportedly discontinuing the development of a heart disease therapy from Ionis Pharmaceuticals after the RNA-targeting drug failed a late-stage trial in September. The decision follows a trial setback for the therapy, leading the Swiss drugmaker to largely abandon the project.
Ionis to hold third quarter 2026 financial results webcast
Ionis Pharmaceuticals (Nasdaq: IONS) announced it will host a live webcast on Monday, November 9, 2026, at 9:00 a.m. Eastern Time. The webcast will cover its third quarter 2026 financial results and provide updates on key programs. A replay of the event will also be available for a limited time.
Ionis Pharmaceuticals (IONS) Sets A Results Webcast, Is The Stock 51% Undervalued?
Ionis Pharmaceuticals (IONS) has scheduled a webcast for November 9, 2026, to discuss its third-quarter results and provide updates on RNA programs. This announcement comes as the stock has seen a significant decline, down 25.1% in 90 days and 48.2% year-to-date, yet analysts and intrinsic value estimates suggest the stock is 51% undervalued with a fair value pegged at $84.13. The webcast is a critical event that could either confirm the current discounted valuation or shift sentiment positively if new information addresses investor concerns.
Ionis to hold third quarter 2026 financial results webcast
Ionis Pharmaceuticals, Inc. announced it will host a live webcast on Monday, November 9, 2026, at 9:00 a.m. Eastern Time. The webcast will discuss the company's third-quarter 2026 financial results and highlight progress on key programs. A replay will be available for a limited time at the same address: https://ir.ionis.com/events-and-presentations/upcoming-events.
Spinal Muscular Atrophy Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight
DelveInsight's "Spinal Muscular Atrophy Pipeline Insight 2026" report provides a comprehensive overview of 19+ companies and 20+ pipeline drugs in development for Spinal Muscular Atrophy. Key takeaways highlight recent advancements from Novartis, Biogen, and Scholar Rock, including updates on clinical trials and regulatory submissions. The report details promising therapies like Salanersen, GC101, and GB221, underscoring a robust and evolving landscape for SMA treatment.
What Ionis Pharmaceuticals Doubters Saw Before The Drop
Ionis Pharmaceuticals experienced a volatile year with a 45.4% loss, marked by both FDA approvals and a significant Phase 3 trial failure. Analysts had diverging fair value estimates at the start of the year, anticipating either strong revenue growth and profit or limited margin improvement due to pricing pressures. The company's current trading price is significantly lower, and its future valuation depends on the success of new therapies like TRYNGOLZA and partnered programs offsetting recent setbacks.
(IONS) as a Liquidity Pulse for Institutional Tactics
This article analyzes Ionis Pharmaceuticals Inc. (NASDAQ: IONS) providing key findings for institutional trading strategies. It highlights a positive near-term sentiment that may shift, weak broader alignment support being tested, and an exceptional risk-reward setup. The analysis offers three distinct AI-generated trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop loss zones, alongside a multi-timeframe signal analysis.
Ionis Pharmaceuticals | 10-Q: Quarterly report
This entry indicates the filing of a 10-Q quarterly report by Ionis Pharmaceuticals. The 10-Q report is a comprehensive financial statement filed by public companies with the U.S. Securities and Exchange Commission (SEC). It provides a detailed overview of a company's financial performance during the most recent quarter.
Ionis Pharmaceuticals, Inc. (IONS) Seasonal returns chart
The article provides a seasonal returns chart for Ionis Pharmaceuticals, Inc. (IONS), displaying the average monthly price return from 2016 to 2026. It includes current stock price data and after-hours trading information for IONS. The page also shows broader market indices and commodity prices.
CCORF Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $85
CCORF has reiterated its Buy rating for Ionis Pharmaceuticals (IONS.US) and maintained a target price of $85. This indicates continued confidence in the company's performance and future prospects from the analyst firm.
Type 2 Diabetes Pipeline Outlook 2026: Oral, Injectable,
A DelveInsight report indicates that the global Type 2 Diabetes pipeline includes over 75 companies developing more than 80 therapeutic candidates, covering oral, injectable, and novel delivery methods. The report highlights emerging therapies like Tirzepatide/LY3298176 and Danuglipron, and recent FDA approvals for drugs such as Novo Nordisk's Awiqli and Eli Lilly's Onswik and Mounjaro, showcasing significant advancements in treatment options, particularly for glycemic control and cardiovascular risk reduction. Key market drivers include the rising disease burden and advances in incretin-based therapies, while barriers involve high development costs and intense competition.
How EU Label Expansion Will Impact Ionis Stock
Ionis Pharmaceuticals received a positive opinion from the EMA's CHMP for an expanded indication of TRYNGOLZA in the EU for severe hypertriglyceridemia, which could significantly boost its commercial reach. This early regulatory momentum, if approved by the EC, would reshape Ionis's revenue mix by expanding beyond rare disease patients. Analysts anticipate substantial revenue and earnings growth for Ionis by 2029, with some bullish forecasts suggesting even greater upside.
Form 8K Ionis Pharmaceuticals Inc For: 23 October By Investing.com
Ionis Pharmaceuticals Inc. (IONS) filed a Form 8K on October 23, 2026. The article from Investing.com announces this filing, noting the company's stock symbol and a slight decrease in its share price. No specific details about the content of the 8K filing are provided.
Ionis Pharmaceuticals, Inc. Estimates – NASDAQ:IONS
This article provides an overview of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) financial actuals and analyst estimates. It allows users to explore reported financial data across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with various estimates and visualizing trends over time. The information is presented as a tool for financial analysis, with a disclaimer noting it is not investment advice.
Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
Ionis Pharmaceuticals and its partner Roche announced positive Phase 3 data from the IMAgINATION study for sefaxersen, an investigational treatment for IgA nephropathy (IgAN). The data showed a statistically significant and clinically meaningful 43.1% reduction in proteinuria at 37 weeks compared to placebo, a key indicator of kidney damage. Sefaxersen, an antisense oligonucleotide, is designed as a once-monthly subcutaneous injection to inhibit complement factor B production, aiming to reduce kidney inflammation and slow disease progression in IgAN patients.
Ionis ranked #1 on Science’s Top Employers list
Ionis Pharmaceuticals, Inc. has been named the top employer in the biotech and pharmaceutical industries by Science in its annual Top Employers survey, rising from #2 last year. The company was recognized for its innovation, talented employees, and strong values-based culture. This recognition is a testament to Ionis's commitment to advancing groundbreaking medicines for patients with serious diseases.
Ionis ranked #1 on Science's Top Employers list
Ionis Pharmaceuticals, Inc. has been named the top employer in the biotech and pharmaceutical industries by Science in its annual Top Employers survey, rising from #2 last year. The company was recognized for its innovation, talented employees, and strong values-based culture. This achievement, in only its second year of eligibility, is attributed to its patient-centric purpose and a culture that encourages exploration and collaboration.
Ionis Pharmaceuticals Secures FDA Orphan Drug Designation For Rare Epilepsy Treatment
Ionis Pharmaceuticals (IONS) has received Orphan Drug Designation from the FDA for ION337, an experimental treatment for Dravet syndrome, a rare genetic disorder causing severe seizures. This designation provides benefits such as tax credits and potential market exclusivity if approved. The company is currently studying ION337 in a Phase 1/2 trial and also has other rare disease treatments in its pipeline, including Obudanersen for Angelman syndrome and Ulefnersen for ALS.
BMO Capital Upgrades Ionis Pharmaceuticals (IONS) to Outperform Ahead of Q3 Earnings
BMO Capital has upgraded Ionis Pharmaceuticals (IONS) from Market Perform to Outperform, raising its price target from $54 to $66. This upgrade is driven by strong early adoption of Ionis's drug Tryngolza for severe hypertriglyceridemia, ahead of the company's Q3 earnings report. Despite currently being unprofitable, Ionis trades below its historical Price-to-Sales median, suggesting market anticipation of future growth.
GSK, Ionis win US approval for first-of-its-kind hepatitis B drug
GSK and Ionis Pharmaceuticals have received U.S. FDA approval for Hibsago, a first-of-its-kind RNA-based medicine for chronic hepatitis B infections. The drug, used in combination with antivirals, aims to provide a "functional cure" by both stopping viral replication and stimulating an immune response. This approval is a significant step for GSK's revenue goals and offers a new treatment option for the 1.7 million people in the U.S. affected by chronic hepatitis B.
Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)
Ionis Pharmaceuticals, Inc. announced that its partner GSK has received U.S. FDA approval for Hibsago (bepirovirsen) for treating chronic hepatitis B (CHB) virus infection in specific adult patients. This first-in-class RNA-targeted medicine, developed in collaboration with Ionis, offers unprecedented functional cure rates compared to the current standard of care. The approval is based on Phase 3 B-Well trials demonstrating a 19% functional cure rate after a six-month treatment course.
Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)
Ionis Pharmaceuticals' partner GSK has received U.S. FDA approval for Hibsago (bepirovirsen) to treat chronic hepatitis B (CHB). This RNA-targeted medicine, developed in collaboration with Ionis, offers a functional cure rate of 19% after six months of treatment for a specific patient population, a significant improvement over existing standard care. The approval is based on Phase 3 data and is a major step forward for the approximately 1.7 million people in the U.S. living with CHB.
Severe Hypertriglyceridemia Market Set for Growth During the Forecast Period (2026-2036) Following Approval of Ionis' TRYNGOLZA and Emergence of Novel Therapies | DelveInsight
The severe hypertriglyceridemia (SHTG) market is projected for significant growth from 2026 to 2036, driven by the increasing prevalence of metabolic disorders and advancements in RNA-based therapeutics. Key market drivers include the recent FDA approval of Ionis' TRYNGOLZA (olezarsen) in June 2026, and the anticipated launch of several emerging therapies from companies like Arrowhead Pharmaceuticals, 89bio, and Eli Lilly. The market is also addressing a substantial unmet need for more effective treatments beyond existing lipid-lowering therapies, with a focus on novel approaches to reduce triglyceride levels and acute pancreatitis risk.
Form 4 Ionis Pharmaceuticals Inc: Shannon L. Devers (EVP, Chief Human Resources Ofc) For: 15 October
This article reports a Form 4 filing for Ionis Pharmaceuticals Inc, detailing an insider transaction by Shannon L. Devers, EVP and Chief Human Resources Officer, for October 15. The filing provides transparency on stock-related activities of company executives. This type of disclosure is a standard regulatory requirement for publicly traded companies.